Population PK/PD Model of Homocysteine Concentrations after High-Dose Methotrexate Treatment in Patients with Acute Lymphoblastic Leukemia

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Rühs, Hauke ^a   Becker, Achim ^a   Drescher, Anne ^a   Panetta, John C ^b   Pui, Ching Hon ^b   Relling, Mary V ^b   Jaehde, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION MODEL; PRESCHOOL CHILD; SIMULATION;

ADOLESCENT; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; FEMALE; HOMOCYSTEINE; HUMANS; INFANT; MALE; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84866686831     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046015     Document Type: Article

References (41)

1. Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, et al. (2004) High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 100 (8): 1724-1733.
2. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, et al. (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11 (7): 2625-2636.
3. Rau T, Erney B, Göres R, Eschenhagen T, Beck J, et al. (2006) High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther 80 (5): 468-476.
4. Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, et al. (2004) Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 10 (17): 5643-5646.
5. Whitehead VM, Vuchich MJ, Cooley L, Lauer SJ, Mahoney DH, et al. (1998) Translocations involving chromosome 12p11-13, methotrexate metabolism, and outcome in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Clin Cancer Res 4 (1): 183-188.
6. Graham ML, Shuster JJ, Kamen BA, Land VJ, Borowitz MJ, et al. (1996) Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study. Clin Cancer Res 2 (2): 331-337.
7. Shuper A, Stark B, Kornreich L, Cohen IJ, Aviner S, et al. (2000) Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol 15 (9): 573-580.
8. Vezmar S, Becker A, Bode U, Jaehde U, (2003) Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49 (1-2): 92-104.
9. Rubnitz JE, Relling MV, Harrison PL, Sandlund JT, Ribeiro RC, et al. (1998) Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 12 (8): 1176-1181.
10. Jaffe N, Takaue Y, Anzai T, Robertson R, (1985) Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 56 (6): 1356-1360.
11. Matsubayashi J, Tsuchiya K, Matsunaga T, Mukai K, (2009) Methotrexate-related leukoencephalopathy without radiation therapy: distribution of brain lesions and pathological heterogeneity on two autopsy cases. Neuropathology 29 (2): 105-115.
12. Refsum H, Ueland PM, Kvinnsland S, (1986) Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine. Cancer Res 46 (10): 5385-5391.
13. Refsum H, Wesenberg F, Ueland PM, (1991) Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 51 (3): 828-835.
14. Becker A, Vezmar S, Linnebank M, Pels H, Bode U, et al. (2007) Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. Int J Clin Pharmacol Ther 45 (9): 504-515.
15. Vezmar S, Schüsseler P, Becker A, Bode U, Jaehde U, (2009) Methotrexate-associated alterations of the folate and methyl-transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity. Pediatr Blood Cancer 52 (1): 26-32.
16. Quinn CT, Griener JC, Bottiglieri T, Hyland K, Farrow A, et al. (1997) Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 15 (8): 2800-2806.
17. Surtees R, Clelland J, Hann I, (1998) Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol 16 (4): 1505-1511.
18. Kishi S, Griener J, Cheng C, Das S, Cook EH, et al. (2003) Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 21 (16): 3084-3091.
19. Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, et al. (2009) Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations. Expert Rev Neurother 9 (9): 1393-1412.
20. Bisschops RHC, van der Graaf Y, Mali WPTM, van der Grond J, (2004) Elevated levels of plasma homocysteine are associated with neurotoxicity. Atherosclerosis 174 (1): 87-92.
21. Mahoney DH, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, et al. (1998) Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy-a Pediatric Oncology Group study. J Clin Oncol 16 (5): 1712-1722.
22. Pui C, Campana D, Pei D, Bowman WP, Sandlund JT, et al. (2009) Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 360 (26): 2730-2741.
23. Ceriotti F, Boyd JC, Klein G, Henny J, Queraltó J, et al. (2008) Reference intervals for serum creatinine concentrations: assessment of available data for global application. Clin Chem 54 (3): 559-566.
24. Broxson EH, Stork LC, Allen RH, Stabler SP, Kolhouse JF, (1989) Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 49 (21): 5879-5883.
25. Faltaos DW, Hulot JS, Urien S, Morel V, Kaloshi G, et al. (2006) Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol 58 (5): 626-633.
26. Min Y, Qiang F, Peng L, Zhu Z, (2009) High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy. Biopharm Drug Dispos 30 (8): 437-447.
27. Dupuis C, Mercier C, Yang C, Monjanel-Mouterde S, Ciccolini J, et al. (2008) High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy. Anticancer Drugs 19 (3): 267-273.
28. Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, et al. (2006) Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet 45 (12): 1227-1238.
29. Piard C, Bressolle F, Fakhoury M, Zhang D, Yacouben K, et al. (2007) A limited sampling strategy to estimate individual pharmacokinetic parameters of methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 60 (4): 609-620.
30. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D, (2004) Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem 37 (8): 684-687.
31. Semmler A, Moskau S, Stoffel-Wagner B, Weller M, Linnebank M, (2009) The effect of MTHFR c.677CT on plasma homocysteine levels depends on health, age and smoking. Clin Invest Med 32 (6): E310.
32. Bremner WF, Holmes EW, Kanabrocki EL, Hermida RC, Ayala D, et al. (2000) Circadian rhythm of serum total homocysteine in men. Am J Cardiol 86 (10): 1153-6, A9-10.
33. Fry DW, Yalowich JC, Goldman ID, (1982) Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem 257 (4): 1890-1896.
34. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, et al. (1996) Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 97 (1): 73-80.
35. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, et al. (1994) Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94 (5): 1996-2001.
36. R Development Core Team (2010) R: A Language and Environment for Statistical Computing. Vienna, Austria. Available: http://www.R-project.org/.
37. Beal SL, Sheiner LB (1998) NONMEM. User's guide. San Francisco: NONMEM project group. University of California.
38. Jonsson EN, Karlsson MO, (1999) Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58 (1): 51-64.
39. Dayneka NL, Garg V, Jusko WJ, (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21 (4): 457-478.
40. Lindbom L, Ribbing J, Jonsson EN, (2004) Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput Methods Programs Biomed 75 (2): 85-94.
41. Lindbom L, Pihlgren P, Jonsson EN, Jonsson N, (2005) PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79 (3): 241-257.